Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-cash Items (2016 - 2025)

Ptc Therapeutics (PTCT) has 10 years of Non-cash Items data on record, last reported at $210.7 million in Q4 2025.

  • For Q4 2025, Non-cash Items rose 230.55% year-over-year to $210.7 million; the TTM value through Dec 2025 reached $210.7 million, up 230.55%, while the annual FY2025 figure was $210.7 million, 230.55% up from the prior year.
  • Non-cash Items reached $210.7 million in Q4 2025 per PTCT's latest filing, up from $151.2 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $210.7 million in Q4 2025 and bottomed at $5.1 million in Q3 2023.
  • Average Non-cash Items over 5 years is $45.1 million, with a median of $9.9 million recorded in 2022.
  • Peak YoY movement for Non-cash Items: tumbled 92.65% in 2022, then skyrocketed 1983.99% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $6.0 million in 2021, then surged by 30.48% to $7.8 million in 2022, then decreased by 1.59% to $7.7 million in 2023, then skyrocketed by 733.09% to $63.7 million in 2024, then soared by 230.55% to $210.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $210.7 million in Q4 2025, $151.2 million in Q3 2025, and $6.5 million in Q2 2025.